YOLFTbeta
Theracryf Plc

Theracryf Plc

TCF · LSE · Healthcare / Biotechnology

0.17GBX+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.17
Open0.17
Day Range0.16 – 0.176
52-Week Range0.16 – 0.268
Volume167.41K
Market Cap3.87M
P/E (TTM)0.00
Forward P/E0.00
EPS0.00
Dividend Yield0.00%
Beta1.36
50-Day Avg0.1875
200-Day Avg0.209

About

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Huw Jones BSc, Ph.D.
  • Employees9
  • HeadquartersAlderley Park, Nether Alderley, United Kingdom, SK10 4TG, UK
  • Websitehttps://theracryf.com

Leadership

  • Dr. Huw Jones BSc, Ph.D.CEO & Executive Director · b. 1959
  • Mr. Toni HaenninenCFO & Director · b. 1977
  • Dr. Helen Kuhlman Ph.D.Chief Operating Officer
  • Dr. Glen Clack FFPM, M.D.Chief Medical Officer

Financials

Income Statement

Currency: GBP2017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue----194.00K0442.00K396.00K0-
Growth (%)------100.00%--10.41%-100.00%-
Cost of Revenue17.00K21.00K21.00K21.00K3.39M16.00K13.00K11.00K2.11M16.00K
Gross Profit-17.00K-21.00K-21.00K-21.00K-3.19M-16.00K429.00K385.00K-2.11M-16.00K
Gross Margin-----1646.91%-97.06%97.22%--
Operating Expense3.63M3.01M3.10M3.13M9.00K3.17M5.50M3.94M12.00K3.67M
Operating Income-3.64M-3.03M-3.12M-3.15M-3.20M-3.19M-5.07M-3.56M-2.12M-3.69M
Operating Margin-----1651.55%--1147.06%-898.99%--
EBITDA-3.63M-3.01M-3.10M-3.15M-3.19M-3.15M-4.99M-3.55M-2.06M-3.67M
EBITDA Margin-----1646.91%--1129.64%-896.21%--
Net Income-3.07M-2.58M-2.62M-2.71M-2.67M-2.73M-4.04M-3.14M-1.94M-3.53M
Net Income Margin-----1378.35%--914.71%-792.17%--
R&D2.10M1.67M1.69M1.70M2.73M2.60M4.72M2.77M398.00K2.76M
R&D as % of Total Revenue----1405.67%-1067.87%699.49%--
Interest Expense3.00K---------

Balance Sheet

Currency: GBP2017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets4.74M4.26M2.76M4.86M12.42M9.64M6.17M3.06M7.63M4.81M
Total Liabilities514.00K389.00K688.00K653.00K607.00K411.00K833.00K721.00K1.66M2.10M
Total Equity4.23M3.87M2.08M4.20M11.81M9.23M5.34M2.34M5.97M2.72M
Cash3.86M3.63M2.03M4.13M5.59M4.51M5.00M2.00M2.11M471.00K
Total Debt---------11.00K
Net Debt-3.86M-3.63M-2.03M-4.13M-5.59M-4.51M-5.00M-2.00M-2.11M-460.00K

Cash Flow

Currency: GBP2017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow-3.19M-2.34M-2.29M-2.58M-2.93M-2.56M-4.03M-3.00M-2.37M-2.55M
Investing Cash Flow1.93M-7.00K--1.00K-6.00M1.48M4.52M--2.08M916.00K
Financing Cash Flow-2.12M694.00K4.67M10.39M---4.55M-7.00K
Capital Expenditure76.00K7.00K01.00K5.00K3.00K1.00K0017.00K
Free Cash Flow-3.27M-2.35M-2.29M-2.58M-2.93M-2.56M-4.03M-3.00M-2.37M-2.56M
FCF to OCF102.38%100.30%100.00%100.04%100.17%100.12%100.02%100.00%100.00%100.67%

Earnings

Report DateMay 31, 2016Dec 5, 2016May 29, 2017Dec 4, 2017Jun 21, 2018Dec 12, 2018Jun 13, 2019Dec 17, 2019Jun 16, 2020Dec 10, 2020Jun 14, 2021Dec 8, 2021Jun 8, 2022Dec 5, 2022Nov 28, 2024Jun 2, 2025Dec 3, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
EPS Actual-0.03-0.02-0.02-0.02-0.01-0.02-0.01-0.01-0.01-0.01-0.01-0.010.00-0.010.000.00-0.00
Surprise-----------------
Timing-----------------

Key Statistics & Ratios

Market Cap3.87M
Enterprise Value264.69K
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.79
Price / Book0.78
EPS0.00
Book Value0.002
Revenue (TTM)0
Gross Profit (TTM)-3.69M
EBITDA-3.69M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-81.30%
Return on Assets-37.12%
Shares Outstanding2.15B
Shares Float1.42B
Beta1.36
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Feb 12, 20211027:1012